The investigational vaccine produced positive interim results in the company’s 1/2a clinical study, which showed that the safety profile and immunogenicity after a single vaccination were supportive of further development.
Johnson & Johnson announced the launch of its large-scale, global phase 3 trial for its COVID-19 vaccine candidate (JNJ-78436735) today in a press release. The vaccine, also known as Ad26.COV2.S, is being developed by its Janssen Pharmaceutical Companies.
The phase 3 trial will enroll up to 60,000 volunteers aged 18 years and older across 3 continents and will evaluate the safety and efficacy of a single vaccine dose compared with placebo in preventing COVID-19. The trial will include significant representation from those that are over the age of 60 years and will include individuals with and without comorbidities associated with an increased risk for progression in severe COVID-19. Read the study protocol here.
For further detail and additional trial coverage, visit Drug Topics
Contemporary OB/GYN Senior Editor Angie DeRosa gets insight on the current state of COVID-19 from Christina Han, MD, division director of maternal-fetal medicine at the University of California, Los Angeles, and member of its COVID-19 task force. Han is an active member of the Society for Maternal-Fetal Medicine and discusses the issues on behalf of SMFM.
Listen
NAID report shows maternal COVID-19 vaccination protects newborns
April 4th 2024New research led by the National Institute of Allergy and Infectious Diseases reveals sustained antibody levels in infants born to vaccinated mothers, underscoring the importance of maternal vaccination in safeguarding newborns against COVID-19.
Read More
Decreased adolescent pregnancy and sexual health care during COVID-19 pandemic
February 13th 2024Adolescent pregnancy and sexual health care utilization declined during the COVID-19 pandemic, indicating significant disruptions in reproductive health services for young females, as highlighted in a recent study published in Pediatrics.
Read More
COVID-19 vaccination during pregnancy not linked to preterm birth
January 31st 2024A systematic review of 6 studies revealed that COVID-19 vaccination during pregnancy does not significantly increase the risk of preterm birth, providing crucial insights for public health policies and offering reassurance to healthcare providers and expectant mothers.
Read More